Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following ...

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) ...

Leiden, the Netherlands Thursday, April 24, 2025, 10:00 Hrs [IST] ...

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final ...

Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million to $335 million, driven by the continued success of RUCONEST and Joenja.

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat activated phosphoinositide ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja ...

RBC Capital lowered the firm’s price target on Pharming (PHAR) to EUR 2 from EUR 2.15 and keeps an Outperform rating on the shares.Don't Miss ...

Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming ...

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS ...

For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older ...